Integra LifeSciences (IART) to Release Quarterly Earnings on Thursday

Integra LifeSciences (NASDAQ:IART) is anticipated to issue its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Integra LifeSciences to post earnings of $0.46 per share and revenue of $414.3080 million for the quarter. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS.Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. The firm had revenue of $415.61 million for the quarter, compared to analyst estimates of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The company’s quarterly revenue was down .6% on a year-over-year basis. During the same quarter last year, the business posted $0.63 earnings per share. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $15.93 on Tuesday. Integra LifeSciences has a fifty-two week low of $11.06 and a fifty-two week high of $27.13. The stock has a market cap of $1.24 billion, a PE ratio of -2.44 and a beta of 1.21. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The firm’s fifty day moving average price is $14.76 and its two-hundred day moving average price is $13.90.

Wall Street Analysts Forecast Growth

IART has been the subject of a number of recent research reports. Truist Financial set a $15.00 target price on Integra LifeSciences and gave the stock a “hold” rating in a report on Wednesday, October 15th. Citigroup reaffirmed a “sell” rating and issued a $12.00 price objective (up previously from $10.00) on shares of Integra LifeSciences in a research note on Tuesday, October 7th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Integra LifeSciences in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $16.17.

Institutional Trading of Integra LifeSciences

Several institutional investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. increased its position in Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the period. Orion Porfolio Solutions LLC boosted its stake in shares of Integra LifeSciences by 30.8% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 41,870 shares of the life sciences company’s stock valued at $514,000 after purchasing an additional 9,856 shares during the last quarter. State of Wyoming boosted its stake in shares of Integra LifeSciences by 84.0% in the 2nd quarter. State of Wyoming now owns 12,953 shares of the life sciences company’s stock valued at $159,000 after purchasing an additional 5,914 shares during the last quarter. Public Sector Pension Investment Board increased its position in shares of Integra LifeSciences by 8.2% during the second quarter. Public Sector Pension Investment Board now owns 227,821 shares of the life sciences company’s stock worth $2,795,000 after buying an additional 17,333 shares during the period. Finally, FORA Capital LLC bought a new position in Integra LifeSciences during the second quarter worth $200,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.